A Study of SH009 Injection in Patients With Advanced Solid Tumors.

Inclusion Criteria: * (1) Age≥18 years old at the time of informed consent, male or female; * (2) Subjects with histologically confirmed locally advanced, recurrent, or metastatic solid tumors (including but not limited to colorectal cancer, gastric cancer, hepatocellular carcinoma, head and neck cancer, breast cancer, non-small cell lung cancer, esophageal cancer, etc.) who have experienced disease progression or intolerance to at least one prior line of systemic therapy, and for whom no acceptable standard therapy exists or who cannot benefit from or tolerate standard therapy; * (3) Subjects must have at least one measurable lesion per RECIST 1.1 criteria. A lesion that has been previously irradiated can only be considered measurable if there is documented progression at that site following radiotherapy; * (4) Archival tumor tissue samples are available, or the subject agrees to undergo a tumor biopsy for the determination of PD-L1 and CD47 expression levels and other biomarker analyses; * (5) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2; * (6) Life expectancy ≥12 weeks; * (7) Bone marrow function meets the following criteria: neutrophil count ≥ 1.5 × 10\^9/L; platelet count ≥ 90 × 10\^9/L (platelet count ≥ 75 × 10\^9/L in patients with liver cancer); hemoglobin (Hb) ≥ 90 g/L; * (8) Liver function meets the following criteria: total bilirubin(TBIL) ≤ 1.5 × ULN (total bilirubin ≤ 3 × ULN for subjects with Gilbert's syndrome); aspartate aminotransfe…